✨ Free AI Report
Juno Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Juno Therapeutics, Inc.
Company Research

Juno Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Juno Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Well-capitalized CAR-T pioneer backed by BMS's resources, with significant 2026 pipeline catalysts. Juno benefits from BMS ownership, which provides robust R&D funding and clinical infrastructure. 2026 is expected to be a big pipeline year for Bristol Myers, with seven pivotal trials expected to read out for experimental drugs, creating.

What is Juno Therapeutics, Inc.'s industry? Juno Therapeutics, Inc. (junotherapeutics.com) operates in Oncology Drugs. AskCyborg classifies Juno Therapeutics, Inc. under Oncology Drugs in its company registry.

Founded in 2013 with a focus on chimeric antigen receptor (CAR) T-cell therapies, Juno quickly established itself as a pioneer in leveraging genetically engineered T-cells for cancer treatment. Now a wholly owned subs...

7/ 10Strong

Cyborg Score thesis

Well-capitalized CAR-T pioneer backed by BMS's resources, with significant 2026 pipeline...

Read the full analyst-debate transcript →
Industry Oncology Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Juno Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Juno Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Juno Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Juno Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Juno Therapeutics, Inc. Overview

Pro stress-test →

Founded in 2013 with a focus on chimeric antigen receptor (CAR) T-cell therapies, Juno quickly established itself as a pioneer in leveraging genetically engineered T-cells for cancer treatment. Now a wholly owned subsidiary of Bristol Myers Squibb, Juno operates as a leading cell therapy unit within one of the world's largest biopharmaceutical companies.

Strategic Profile

Pro stress-test →

Juno is an integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer, having developed cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Following Bristol-Myers Squibb's completion of its acquisition of Celgene in November 2019, Juno has been integrated into BMS's oncology and cell therapy portfolio, positioning it to leverage the parent company's scale and resources.

Competitive Landscape

Pro stress-test →

Juno competes within the CAR-T cell therapy and advanced cellular immunotherapy space against Kite Pharma (Gilead), Novartis, Celldex, Autolus, and emerging private cell therapy companies. As a BMS subsidiary, Juno's competitive positioning is strengthened by parent company resources, manufacturing scale, and global commercialization infrastructure, though it faces intense competition in CAR-T approvals and next-generation cell therapy approaches.

Industry Context

Juno Therapeutics, Inc. operates in Oncology Drugs.

Key facts

Founded: 2013 · Headquarters: Seattle, US · Revenue: N/A · Market cap: N/A

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Juno Therapeutics, Inc..

  • Acquired by Bristol Myers Squibb in 2020 (via Celgene) for approximately $9 billion, Juno's integration into BMS has significantly influenced the competitive dynamics within the rapidly evolving biotech landscape, particularly in the CAR-T and next-generation immunotherapies sector
  • Seven pivotal trials are expected to read out in 2026 for experimental drugs under Bristol Myers, providing near-term catalysts for Juno's pipeline advancement
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • June 2025Transfer of Juno Therapeutics GmbH German subsidiary to TQ Therapeutics to accelerate cell therapy development
  • April 2025Raised $129 million in funding to expand research infrastructure and clinical trial capabilities
  • +1 moreTrack every material event for Juno Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Juno Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

YescartaCAR-T cell therapy for lymphomas→KymriahCAR-T cell therapy for hematologic malignancies→BreyanziApproved CAR-T therapy for relapsed/refractory lymphoma→TecartusCAR-T therapy for mantle cell lymphoma→

Compare Juno Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Juno Therapeutics, Inc. operates in Oncology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Oncology Drugs research →
NEW · MCP server

Ask your AI assistant about Juno Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Juno Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Juno Therapeutics, Inc. do this quarter?”
“Is Juno Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Juno Therapeutics, Inc. do?+
Founded in 2013 with a focus on chimeric antigen receptor (CAR) T-cell therapies, Juno quickly established itself as a pioneer in leveraging genetically engineered T-cells for cancer treatment. Now a wholly owned subs...
What is Juno Therapeutics, Inc.'s Cyborg Score?+
Juno Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Juno Therapeutics, Inc.'s main competitors?+
Named competitors include Yescarta, Kymriah, Breyanzi, Tecartus. The full competitive landscape is in the AskCyborg report.
How can I get the full Juno Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Juno Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Juno Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.